Shipments of Ph(2)(TM) Expected to Commence November 2015
LONDON, UK / ACCESSWIRE / October 12, 2015 / Plandaí Biotechnology, Inc. ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has executed a distribution agreement covering 14 SADIC countries with Coyne Healthcare, a South African-based distributor of nutraceuticals and food supplements (http://coynehealthcare.co.za/). Under the terms of the agreement, Coyne Healthcare will market the Company's Ph(2)(TM) Pheroid(R) entrapped Phytofare(R) catechin complex in a finished product format to pharmacies, health food stores and medical practitioners for oral administration. The three-year renewable agreement calls for a sales minimum of 30,000 blister packs in year one, escalating over subsequent years.
Callum Cottrell-Duffield, Vice President of Sales for Plandaí, commented, "We are excited to partner with Coyne Healthcare to distribute Plandaí products in our backyard of South Africa. They have an excellent reputation and a proven track record in nutraceutical sales. Ph(2)(TM) is a powerful anti-oxidant and will be sold as a finished product targeting weight loss, increased energy and vitality, anti-aging, and anti-inflammatory indications."
The Ph(2)(TM) catechin complex has been under development for the previous year in collaboration with North West University. Clinical trials released May 2015 demonstrated that Pheroid(R)-entrapped Phytofare(R) delivers in a controlled dosage greater bioavailability with no side effects and no metabolization in the digestive tract. What this means is that a greater portion of the phyto-nutrients reach the bloodstream and the target cells. When the Phytofare(R) catechin complex is entrapped in Pheroid(R), the resultant product, trade named Ph(2)(TM), delivers increased phyto-availability(TM) over generic green tea extracts. Ph(2)(TM) releases the full profile of 8 catechins which then remain in the bloodstream at therapeutic levels for over 24 hours. Generic green tea extracts, by comparison, generally contain only two catechins, are heavily metabolized into less-effective metabolites during digestion, and are then eliminated from the bloodstream after a few hours.
Company Chief Executive Roger Baylis-Duffield added, "This is an exciting time for Plandaí. The weather has provided ideal growing conditions enabling us to commence production a two weeks ago and well ahead of schedule. Our various distributors are gaining traction in their markets, and we are active in preparing the Phytofare(R) limonoid complex for market. Our new Ph(2)(TM) product gives customers greater flexibility either as an ingredient or a finished product, complementing the Phytofare(R) catechin complex we released in past April."
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available(TM) extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare(R) extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.
CONTACT:
Jessica Snyder-Gutierrez
602-561-7549
SOURCE: Plandaí Biotechnology, Inc.
